Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 2
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Kazda CM, et al. Diabetes Care. 2016 Nov;39(11):e199-e200. doi: 10.2337/dci16-0030. Diabetes Care. 2016. PMID: 27926898 No abstract available.
Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.
Guzman CB, Duvvuru S, Akkari A, Bhatnagar P, Battioui C, Foster W, Zhang XM, Shankar SS, Deeg MA, Chalasani N, Hardy TA, Kazda CM, Pillai SG. Guzman CB, et al. Among authors: kazda cm. Hepatol Commun. 2018 Mar 23;2(5):561-570. doi: 10.1002/hep4.1171. eCollection 2018 May. Hepatol Commun. 2018. PMID: 29761171 Free PMC article.
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Kazda CM, et al. Diabetes Care. 2017 Jun;40(6):808. doi: 10.2337/dc17-er06. Epub 2017 Apr 18. Diabetes Care. 2017. PMID: 28420698 Free PMC article. No abstract available.